Indian Journal of Cancer Home 

ORIGINAL ARTICLE
[View FULLTEXT] [Download PDF]
Year : 2018  |  Volume : 55  |  Issue : 2  |  Page : 157--161

The efficacy and tolerability of scalp cooling in preventing chemotherapy-induced alopecia in patients with breast cancer receiving anthracycline and taxane-based chemotherapy in an Asian setting

Marniza Saad1, Flora Li Tze Chong1, Anita Zarina Bustam1, Gwo Fuang Ho1, Rozita Abdul Malik1, Wan Zamaniah Wan Ishak1, Vincent Chee Ee Phua1, Mastura Md Yusof2, Ning Yi Yap3, Adlinda Alip1 
1 Clinical Oncology Unit, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
2 Clinical Oncology Unit, Faculty of Medicine, University of Malaya; Pantai Cancer Institute, Pantai Hospital Kuala Lumpur, Malaysia
3 Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

Correspondence Address:
Dr. Adlinda Alip
Clinical Oncology Unit, Faculty of Medicine, University of Malaya, Kuala Lumpur
Malaysia

BACKGROUND: Scalp cooling has been shown in several studies to be an effective method in preventing chemotherapy-induced alopecia (CIA). Data on the use of scalp cooling in Asian countries are limited, and evidence for its use and efficacy among our patients are not available. OBJECTIVE: The aim of this study was to assess the effectiveness and tolerability of scalp cooling among breast cancer patients in our study population. METHODS: Consecutive breast cancer patients receiving FE75C, FE100C, FE100C-D, docetaxel75 or docetaxel, and cyclophosphamide (TC) at our treatment center were recruited and allocated to the treatment (scalp cooling, DigniCapTM system) or control group in this prospective nonrandomized controlled study. The assessment of alopecia was carried out using the World Health Organization grading system and clinical photographs. RESULTS: Seventy patients were recruited, but only 25 completed the study and were evaluable for analysis. Five of 12 patients (42%) in the scalp cooling group managed to preserve hair. Two of three patients who received FE75C and TC regimens had minimal hair loss. All patients treated with FE100C had severe hair loss. Half of all patients who received scalp cooling throughout chemotherapy rated the treatment as reasonably well tolerated. The most common reason for discontinuing scalp cooling was intolerance to its side effects. CONCLUSION: Scalp cooling is potentially effective in reducing CIA caused by docetaxel, TC, and FE75C chemotherapy regimen. However, it was not well tolerated by our study population. The dropout rate was high, and this needs to be taken into consideration when pursuing further trials in a similar setting.


How to cite this article:
Saad M, Chong FL, Bustam AZ, Ho GF, Malik RA, Ishak WZ, Ee Phua VC, Yusof MM, Yap NY, Alip A. The efficacy and tolerability of scalp cooling in preventing chemotherapy-induced alopecia in patients with breast cancer receiving anthracycline and taxane-based chemotherapy in an Asian setting.Indian J Cancer 2018;55:157-161


How to cite this URL:
Saad M, Chong FL, Bustam AZ, Ho GF, Malik RA, Ishak WZ, Ee Phua VC, Yusof MM, Yap NY, Alip A. The efficacy and tolerability of scalp cooling in preventing chemotherapy-induced alopecia in patients with breast cancer receiving anthracycline and taxane-based chemotherapy in an Asian setting. Indian J Cancer [serial online] 2018 [cited 2021 Jun 12 ];55:157-161
Available from: https://www.indianjcancer.com/article.asp?issn=0019-509X;year=2018;volume=55;issue=2;spage=157;epage=161;aulast=Saad;type=0